Add BrightSurf on Google Email

Does weight loss surgery affect colorectal cancer risk?

A study published in the International Journal of Cancer suggests that weight loss surgery may increase the risk of colon cancer. Patients who underwent such surgery had a higher risk of colon cancer compared to the general population, especially over time.

SourceWiley·JournalInternational Journal of Cancer·DateDec 4, 2019

A novel pathway to target colorectal cancer

A new study published in Gastroenterology reports that prostaglandin E2 (PGE2) promotes metastasis of colorectal cancer through the microRNA MIR675-5p, which silences the expression of p53. Researchers found that mice treated with PGE2 had increased metastases compared to controls, and tumor cells expressed more MIR675-5p and less p53.

SourceMedical University of South Carolina·JournalGASTROENTEROLOGY·DateNov 26, 2019

Triplet-targeted therapy improves survival for patients with advanced colorectal cancer and BRAF mutations

The BEACON CRC Phase III clinical trial found that the three-drug combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival in patients with BRAF-mutated metastatic colorectal cancer. Median OS for the triplet-targeted therapy was 9 months compared to 5.4 months for standard therapy.

SourceUniversity of Texas M. D. Anderson Cancer Center·JournalNew England Journal of Medicine·DateSep 30, 2019

Novel treatment combination for patients with BRAF-mutant metastatic colorectal cancer

A phase III study showed that the combination of encorafenib, binimetinib, and cetuximab significantly improved overall survival (9.0 months) and objective response rates compared to standard care. The treatment was well-tolerated, suggesting a potential paradigm shift in treating BRAF-mutant metastatic colorectal cancer.

SourceVall d'Hebron Institute of Oncology·JournalNew England Journal of Medicine·DateSep 30, 2019

Factors associated with longer wait times in colorectal cancer specialty care referrals

A study found that patients presenting with non-alarming gastrointestinal symptoms experienced longer wait times for referral, while those with red flag symptoms had shorter wait times. The study highlights the need for earlier reconsideration of initial diagnoses and strict follow-up consultations to reduce wait times.

SourceAmerican Academy of Family Physicians·JournalThe Annals of Family Medicine·DateSep 9, 2019

Providing more testing choices does not increase colorectal cancer screening rates

A new study from the University of Pennsylvania School of Medicine found that providing patients with more testing choices, such as home fecal immunochemical testing (FIT), does not increase participation in colorectal cancer screening. However, framing choice did impact patient decision-making, leading to a decrease in colonoscopy rates.

SourceUniversity of Pennsylvania School of Medicine·JournalJAMA Network Open·DateAug 30, 2019

Physical activity in adolescence and later life reduces the risk of colorectal adenoma

A study analyzing data from almost 30,000 nurses found that physical activity in adolescence and later life cumulatively reduce the risk of advanced adenomatous polyps, a precursor to colorectal cancer. The study showed that adequate physical activity in both adolescence and adulthood reduces the risk by 39%.

SourceFundação de Amparo à Pesquisa do Estado de São Paulo·JournalBritish Journal of Cancer·DateAug 19, 2019

Colorectal cancer rates in Canada

The incidence of colorectal cancer among younger adults in Canada has increased over the past few decades. The study found that men under 50 had an average annual percentage change of 3.47% and women under 50 had a 4.45% increase from 2006 to 2015.

SourceJAMA Network·JournalJAMA Network Open·DateJul 31, 2019

Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

A study at ESMO World Congress on Gastrointestinal Cancer 2019 found that a more flexible dosing regimen for regorafenib improves patients' quality of life while maintaining its efficacy. The reduced and intermittent dose groups showed numerical improvements in tolerance to side effects such as fatigue and hand-foot syndrome.

SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateJul 6, 2019